



PRESS RELEASE

2000-11-30

Affärsstrategerna invests in Biotech

Affärsstrategerna invests 2 MSEK in ARCTIC BioPharm Production AB, which business idea is to offer customers production development through special cell culturing technique for manufacturing of new patient tailor made bio technical pharmaceuticals, as well as production filling of external customer's pharmaceuticals and vaccines.

The founders of the company, CEO Torgny Lundgren and Dr. Maorong Ruan, R&D Director, both have vast and profound experience and competence to establish and build biotech companies regarding validation and documented processes according to FDA (Food and Drug Administration) requirements and regulations, which approves manufacturing of contract produced bio technical pharmaceuticals.

ARCTIC already has a Letter-of-Intent from one of the big research&development companies of pharmaceuticals, regarding pharmaceutical filling of one of their registered drugs. ARCTIC will be able to offer full service products in a modern high-tech facility in Luleå, north of Sweden. The potential market of so called outsourcing, for contract production and research oriented development projects, amounts to several billion SEK and has a yearly growth of 25-30%.

- Affärsstrategerna is a competent partner and they have long experience and track record of creating successful medical and biotech companies, says Torgny Lundgren, founder and CEO of ARCTIC.

- Individual tailor made pharmaceuticals for the patient will soon be a matter of course and we also believe that contract development and production of bio technical pharmaceuticals, have an enormous potential in the future, says Claes-Göran Fridh, President and founder of Affärsstrategerna.

Affärsstrategerna's investment of 2 MSEK in ARCTIC represents 21% of the share capital, of which 5% will be used for a stock option program to employees.

For further information, please contact:

Yvonne Petersson, Business Developer, Affärsstrategerna i Sverige AB
telephone +46-8-545 831 92 or e-mail: yvonne@astrateg.se

Torgny Lundgren, CEO, ARCTIC BioPharm Production AB
telephone +46-705-95 55 27 or e-mail: torgny.lundgren@mbox300.swipnet.se

Affärsstrategerna is a leading seed investment venture capital company listed on the OM Stockholm Stock Exchange O-list. Affärsstrategerna invests value-added capital in innovative start-ups, operating in IT/Internet, Wireless and Life Science/Medical Technology, and has the potential to become market leader in its niche. Some of the companies in the portfolio are: A Brand New World, Alpha Helix, ARCTIC BioPharm Production, Artema, Chemel, Doorways Education, European Institute of Science, Fingerprint Cards, FreeHand Communication, InfiniCom, Mainbox, Megacon, Mocat, Musicbrigade, Naty, Netbaby World, RaySearch Laboratories, RS Cordless Technology, Samba Sensors, Skolboken.se, SWATS, Webupdate, Widermind and Yesitworks.com





Artillerigatan 6 · 114 51 Stockholm · Telefon 08-662 40 30
Fax 08 660 83 19 · e-mail: info@astrateg.se · Internet: www.astrateg.se